Cargando…

CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth

CD47 is a glycoprotein of the immunoglobulin superfamily that is often overexpressed in different types of hematological and solid cancer tumors and plays important role in blocking phagocytosis, increased tumor survival, metastasis and angiogenesis. In the present report, we designed CAR (chimeric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golubovskaya, Vita, Berahovich, Robert, Zhou, Hua, Xu, Shirley, Harto, Hizkia, Li, Le, Chao, Cheng-Chi, Mao, Mike Ming, Wu, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664078/ https://www.ncbi.nlm.nih.gov/pubmed/29065481 http://dx.doi.org/10.3390/cancers9100139

Ejemplares similares

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
por: Golubovskaya, Vita, et al.
Publicado: (2023)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth
por: Golubovskaya, Vita, et al.
Publicado: (2023)

Hypoxia Selectively Impairs CAR-T Cells In Vitro
por: Berahovich, Robert, et al.
Publicado: (2019)

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
por: Golubovskaya, Vita, et al.
Publicado: (2016)

DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers
por: Sureban, Sripathi M., et al.
Publicado: (2019)

CAR-T Cell Therapy: From the Bench to the Bedside
por: Golubovskaya, Vita
Publicado: (2017)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis
por: La, Huyen Thi, et al.
Publicado: (2021)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
por: Wu, Lijun, et al.
Publicado: (2022)

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer
por: Shu, Runzhe, et al.
Publicado: (2021)

CD47-Blocking Antibodies and Atherosclerosis
por: Ryan, John J.
Publicado: (2016)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
por: Ambrose, Christine, et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

The application of HER2 and CD47 CAR-macrophage in ovarian cancer
por: Chen, Yizhao, et al.
Publicado: (2023)

Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
por: Wang, Lingyan, et al.
Publicado: (2022)

Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”
por: Golubovskaya, Vita
Publicado: (2023)

Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
por: Yang, Hongcheng, et al.
Publicado: (2019)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

New insights into CAR T cell-mediated killing of tumor cells
por: Espie, David, et al.
Publicado: (2022)

Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57
por: Zhu, Xuekai, et al.
Publicado: (2014)

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs
por: Anikeeva, Nadia, et al.
Publicado: (2021)

Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment
por: Qiu, Yingqi, et al.
Publicado: (2023)

CD47 blocking antibodies restore phagocytosis and prevent atherosclerosis
por: Kojima, Yoko, et al.
Publicado: (2016)

Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023)

CAR-NK Cells: From Natural Basis to Design for Kill
por: Khawar, Muhammad Babar, et al.
Publicado: (2021)

Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells
por: Pourzia, Alexandra L., et al.
Publicado: (2023)

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
por: Yu, Jifeng, et al.
Publicado: (2022)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
por: Liao, Qibin, et al.
Publicado: (2020)

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
por: Schoutrop, Esther, et al.
Publicado: (2022)

The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination
por: Shi, Rui, et al.
Publicado: (2020)

CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation
por: Gondois-Rey, Françoise, et al.
Publicado: (2022)

Regulation of CD47 expression in cancer cells
por: Huang, Can-Yu, et al.
Publicado: (2020)

Infected Cell Protein (ICP)47 Enhances Herpes Simplex Virus Neurovirulence by Blocking the CD8(+) T Cell Response
por: Goldsmith, Kim, et al.
Publicado: (1998)

Editorial on Special Issue “Immunotherapy, Tumor Microenvironment and Survival Signaling”
por: Golubovskaya, Vita
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s4rhj7dsl8egb9rtacmtdt3fr3